<DOC>
	<DOCNO>NCT00521222</DOCNO>
	<brief_summary>The investigator conduct study asthma patient use fluticasone salmeterol ( Advair ) combination inhale corticosteroid ( ICS ) long act beta agonist ( LABA ) manage asthma symptom . Participants begin study continue use fluticasone salmeterol substitute fluticasone salmeterol current ICS/LABA medication regular dose comparable dose ( study medication provide ) six-week period . Patients separate 2 group : one group ask use fluticasone ( Flovent ) , use fluticasone salmeterol , twice daily 16-week period ( patient need see monthly time ) . Neither study personnel patient know drug use . Patients also ask use peak flow meter record daily result form , along number puff use rescue inhaler day . They also record change asthma medication information asthma episode . The investigator hypothesize certain patient asthma well long act beta agonist remove maintenance asthma medication .</brief_summary>
	<brief_title>Evaluating Long Acting Beta Agonists Used Treat Asthma Among Those With Either Arg/Arg Gly/Gly Genotypes</brief_title>
	<detailed_description>Beta 2 ( b2 ) agonists common type bronchodilator use treat asthma . Beta 2 ( b2 ) agonists agent bind b2 receptor cause muscle relaxation airway . There different variant gene ( genotype ) influence b2 agonist perform among population . A recent study demonstrate patient mild asthma Arg/Arg variant 16th amino acid position improve lung function asthma control albuterol ( Proventil-HFA ) , short act b2 agonist , replace different class bronchodilator . The investigator plan study asthma patient distinct genetic makeup b2 receptor ; specifically Arg/Arg Gly/Gly . Throughout treatment period , patient instruct use ipratropium bromide ( Atrovent-HFA ) , bronchodilator work different mechanism rescue therapy ; albuterol available use necessary . The goal study determine withdrawal beta 2 agonist lead improve asthma control asthmatic patient Arg/Arg genotype compare Gly/Gly genotype .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Age 18 year old History moderate severe persistent asthma Currently treat long act beta agonist inhale corticosteroid FEV1 &gt; = 70 % randomization visit ( pulmonary function test result ) Women childbearing potential must effective form contraception Ability read understand English Active smoking great 10packyear history smoke History intubation asthma within past 10 year Patients pregnant , become pregnant study breast feed Major comorbidity include : severe cardiac disease , uncontrolled hypertension , poorly control diabetes , malignancy within past 5 year ( except nonmelanoma skin lesion ) , pulmonary disease asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>beta agonist</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>pulmonary</keyword>
	<keyword>genotype</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>allergy</keyword>
	<keyword>immunology</keyword>
</DOC>